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The recognition of a series of metabolic/enzymatic dysfunctions 
in glycogenoses has allowed new therapeutic advances for their 
treatment due to the development of recombinant enzyme. A re-
cent advance appears enzymatic replacement therapy (ERT) in 
glycogenosis type II in both infantile, juvenile and adult form. 
Targeted manipulation of diet has been tried both in glycogenosis 
type II (Pompe disease) and type V (Mc Ardle disease). 
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Introduction
Glycogenoses are a group of diseases characterized 
by an impairment in energy production in skeletal mus-
cles. They include defects in glycogen synthesis, glyco-
gen breakdown or glycolysis (Table 1). Clinically, they 
range from multisystemic and rapidly fatal diseases, to 
isolated slowly progressive myopathies (e.g. glycogeno-
sis type II), or to episodic muscle dysfunction during ex-
ercise (e.g. McArdle’s disease). A rapid diagnosis is now 
increasingly important to give patients the chance of the 
new treatments becoming available in the last years.
Glycogenosis type II
Glycogen storage disease type II (GSDII) is an au-
tosomal recessive disorder caused by the deficiency of 
the lysosomal enzyme acid α-glucosidase (GAA) or ac-
id maltase, which catalyses the hydrolysis of α-1,4 and 
α-1,6 linkages of glycogen. The enzyme deficiency leads 
to lysosomal accumulation of glycogen that results in dif-
ferent clinical phenotypes (severe or infantile, juvenile 
and adult onset). 
The severe infantile form of GSDII (Pompe disease) 
is characterized by marked hypotonia and cardiomyopa-
thy usually due to complete GAA deficiency, and patients 
die within the first year of life, if untreated, for cardiores-
piratory failure (1).
The juvenile and adult forms, named late-onset GS-
DII, are slowly progressive myopathies mimicking limb-
girdle  dystrophy,  frequently  characterized  by  an  early 
respiratory involvement with diaphragmatic paralysis and 
restrictive respiratory insufficiency (2); a residual enzyme 
activity is usually found (3).
The histopathological hallmark is muscle fiber vacu-
olization and autophagy. The vacuoles can vary for size 
and shape, show PAS-positivity and strong reaction for 
lysosomal  acid  phosphatase.  In  the  infantile  form,  the 
muscle fiber structure is severely compromised, while the 
degree of vacuolization is extremely variable in late-onset 
patients, and appeared sometimes to be independent of 
age of onset, disease duration or clinical features (3).
Genotype-phenotype  correlations  showed  that  al-
though the nature of the mutation sometimes matches the 
phenotype, in most cases the disease phenotype is hard 
to predict on the basis of gene mutations alone. Further-
more, the age at onset and the disease course may be 
quite different in patients with identical genotypes (e.g. 
siblings), suggesting a modulating role of both the ge-
netic background and of exogenous factors on GAA gene 
expression, which might produce a shift in the enzyme 
biosynthesis rate (3).
Knowledge of the natural history of the late-onset 
disease is still poorly investigated, mostly because of its 
extremely heterogeneous course.
Trials with replacement therapies
Several  replacement  therapies  have  been  tried  in 
GSDII patients since 1967, when an enzyme derived 
from  Aspergillus  niger  was  unsuccessfully  tested (4). 
Decades ago it was recognized that various cell types 
need specific receptors for uptake of exogenous lyso-
somal enzymes. In muscle and liver it was the mannose-
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Acid alpha-glucosidase II - - + +
Debrancher III - - + +






Aldolase A XII - + - -
PFK VII + + - -
PGK1 IX + + - -
PGAM X + + - -
Enolase B XIII + + - -






Glycogen synthetase 0 + - - +













Phosphorylase kinase VIII - + - +
Glycogenin-1 - - - + +
Table 2. Italian GSDII patients treated with enzyme replacement therapy.
Number %
Clinical features Patients 78  




Age at onset (years)
Average 29  
SD 15  
Range 1 - 60  
Disease duration at start of ERT (years)
Median 14  
SD 8  
Range 1 - 35  
Walking
Yes 52 66
Unilateral support  9 11
Bilateral support 10 12




 < 12 h 7 9
 > 12 h 13 16
Cardiomyopathy Yes 7 9
  No 71 91
ERT duration (months)
Range 12 - 54  




None 72 92State of the art in muscle glycogenoses
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6-phosphate receptor (M6P). This gave new chance to 
the research. 
In  the  meantime,  other  therapeutical  options  have 
been tried. A dietary treatment with high-protein and low-
carbohydrates, with supplementation with L-alanine, and 
associated with physical aerobic sub-maximal exercise (5) 
was proposed. The purpose of the dietary treatment was 
to decrease the deposition of glycogen in lysosomes, and 
to antagonize the protein catabolism in muscles observed 
in GSDII patients’ tissues, and stimulating fatty-acid uti-
lization in muscles as an energy source during aerobic 
exercise. The theoretic substrate of this therapy is con-
firmed by the case of a 26-year old patient, followed at 
our center, who presented acute respiratory failure after 
2 months of vegetarian diet, resolved after ventilatory 
therapy and hyperproteic diet. The clinical outcome in 
Slonim’s study was surprisingly good, even if the compli-
ance to the scheme was not easy, and the increase of body 
weight of some patients worsened their motor function.
In 2000 Genzyme-Pharming announced the discon-
tinued development of enzyme replacement therapy with 
recombinant human enzyme from rabbit milk, then Gen-
zyme believed the production in CHO cells to be quicker 
and more efficient. 
recombinant enzyme replacement
In infantile Pompe disease an enzyme replacement 
treatment  with  recombinant  alpha-glucosidase  (rGAA) 
has been tried both in the US and Europe (1, 6), with ma-
jor benefits on survival and cardiomyopathy.
Only relatively few treated late-onset patients in Eu-
rope have been so far extensively reported (7-9). This fact 
demonstrates that it is difficult to compare the action of 
ERT in late-onset cases, because of the heterogeneous 
clinical features and the slow progression of the disease in 
those patients. Since ERT treatment has been approved in 
Europe, a blind trial would not be accepted by patients and 
therefore it is now impossible to carry it out. Otherwise, 
it is important to investigate in a multidisciplinary and 
quantitative way the treated GSDII patients, to describe 
the natural course of the disease, to underline the benefits 
of ERT and to identify the non-responder patients. We are 
conducting a multicenter observational study in 18 centers 
in Italy that has so far collected 78 treated cases including 
walking and non-walking patients (Table 2).
It is clear that ERT is a safe therapy: only mild infu-
sion-related adverse reactions have been observed (Table 
2). It is clear that ERT is effective in infantile form, es-
pecially on reducing the cardiomegaly and prolong the 
survival. Otherwise it is not easy to demonstrate the real 
efficacy of the therapy in late-onset GSDII, on the slowly 
progressive motor and respiratory failure, and the long 
term efficacy. A randomized double-blind study has been 
done in 60 walking patients proving an efficacy, although 
of modest degree, in 6-minute-walk-test and stabilization 
of respiratory function (10).
The most important limits of the enzymatic therapy 
are the difficulty to reach the target, in muscles fibers 
were the M6P receptors density is much lower than in the 
heart, and the formation of antibodies that may reduce 
the efficacy of the protein and the presence of structural 
alteration of muscle with build up of connective tissue. 
The first one can be overcome by the conjugation of the 
recombinant  enzyme  with  a  synthetic  oligosaccharide 
containing M6P (11), resulting in an improved affinity for 
the M6P receptor and delivery to muscle cells. The use of 
chaperones is still experimental and their use in two US 
patients has led to more pronounced weakness.
Glycogenosis type V – Mcardle 
Disease
McArdle  disease  is  a  metabolic  myopathy  caused 
by the genetic deficiency of the glycolytic enzyme myo-
phosphorylase. It is clinically characterized by exercise 
intolerance, fatigue and exercise induced myalgia, and, 
in some cases, by myoglobinuria resulting in acute renal 
failure due to rhabdomyolysis. A small proportion of pa-
tients develop a progressive weakness of proximal mus-
cles, especially of upper limbs. 
The  enzymatic  defect  causes  a  global  impairment 
in  muscle  metabolism.  The  impossibility  to  mobilise 
glycogen  subsarcolemmal  deposits  during  anaerobic 
metabolism,  the  reduction  of  pyruvate  production  in 
the tricarboxylic acid cycle and the subsequent oxida-
tive phosphorylation impairment bring to a reduction of 
Acetyl-CoA production, with a cyclic worsening of func-
tion of tricarboxylic acid cycle.
The breakdown of fatty acid can, in some trained 
patients, generate some alternative quantities of Acetyl-
CoA; the shift to fatty acid oxidation is the basis of the 
“second wind” phenomenon, the possibility of patients to 
continue the exercise after some minutes of rest, when the 
pain occurs.
Many  drugs  or  dietary  treatments  have  been  tried 
to reduce symptoms in this rare disease, but all of them 
failed to demonstrate a significant amelioration in these 
patients. It is important to underline that every study was 
designed with a small number of patients, furthermore 
the clinical heterogeneity prevented the establishment of 
measurable primary outcomes.
Aminoacids, high protein diet, and fatty acid supple-
mentation have been tried to improve alternative energy 
sources instead of glycolytic metabolism (12), but only in 
single anecdotic cases a success has been claimed.C. Angelini
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